QDEL - QuidelOrtho Corporation

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $12.25 DETAILS

Stock News

When Blood Compatibility Becomes a Pregnancy Risk

SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation.

May 21, 2026 05:18 AM • prnewswire.com

QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences

SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026 Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m.

May 20, 2026 03:00 AM • prnewswire.com

Hantavirus outbreak: these 3 stocks are poised to rip higher

The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed fatalities and a widening caseload linked to the South Atlantic itinerary have forced an urgent global response to intercept a pathogen characterized by high lethality and rapid pulmonary onset.

May 11, 2026 07:44 PM • invezz.com

QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y

QuidelOrtho posts a wider Q1 loss as revenues fell 10.5% year over year, with weakness in respiratory testing pressuring margins and cash flow.

May 06, 2026 09:21 AM • zacks.com

QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript

May 06, 2026 01:31 AM • seekingalpha.com

QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates

QuidelOrtho (QDEL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of $0.37. This compares to earnings of $0.74 per share a year ago.

May 05, 2026 03:10 PM • zacks.com

QuidelOrtho Reports First Quarter 2026 Financial Results

― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ― ― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ― ― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $620 million, as reported Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.

May 05, 2026 12:05 PM • prnewswire.com

Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline

QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apr 28, 2026 07:06 AM • zacks.com

QuidelOrtho Corp (QDEL) Shares Surge 6.1% -- What GF Score of 60 Tells Investors

On April 27, 2026, QuidelOrtho Corp (QDEL) shares rose 6.1% today, currently trading at $12.29. The stock has experienced a volatile year, with a 52-week range

Apr 27, 2026 02:22 PM • gurufocus.com

Understanding and Addressing Syphilis Trends - and What's Being Missed

SAN DIEGO, April 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving syphilis trends in the United States and the rise of congenital syphilis cases despite declines in early-stage infections. Hosted by Josh Casey, the episode features Andrea Ott‑Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, who breaks down what CDC data reveals, why congenital syphilis continues to rise and how diagnostic strategies and healthcare workflows can close critical screening gaps, especially during pregnancy.

Apr 23, 2026 05:32 AM • prnewswire.com

United Health Products (OTCMKTS:UEEC) and QuidelOrtho (NASDAQ:QDEL) Financial Comparison

QuidelOrtho (NASDAQ: QDEL - Get Free Report) and United Health Products (OTCMKTS:UEEC - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations. Earnings and Valuation This table compares QuidelOrtho

Apr 23, 2026 12:54 AM • defenseworld.net

TTP Group Announces the Sale of LEX Diagnostics

CAMBRIDGE, England--(BUSINESS WIRE)--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group. Founded in 2020, LEX Diagnostics originated from a TTP innovation programme to translate a breakthrough in ultra-fast thermal control into a commercially viable diagnostic solution. This work led to the development of a point-of-care molecular.

Apr 20, 2026 03:56 AM • businesswire.com

QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

– Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics – – Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less – – Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year – SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026.

Apr 20, 2026 03:12 AM • prnewswire.com

QuidelOrtho Looks Mispriced If 2026's FCF Turnaround Materializes

QuidelOrtho's (QDEL) reported weakness is concentrated in post-COVID Point of Care and the deliberate US donor-screening exit. However, the rest of their portfolio is actually growing. Labs is the primary revenue engine, contributing 55% of sales in 2025. Likewise, Immunohematology also expanded and supports a healthier underlying mix.

Apr 18, 2026 09:16 AM • seekingalpha.com

QuidelOrtho Stock Sinks To 52-Week Low - Here's Why

The diagnostic healthcare products maker reported preliminary unaudited revenue in the range of $615 million to $620 million for the first quarter, compared to the consensus of $680.59 million.

Apr 16, 2026 09:45 AM • benzinga.com

QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance

SAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes.

Apr 15, 2026 12:15 PM • prnewswire.com

QuidelOrtho Corp (QDEL) Shares Surge 7.7% -- What GF Score of 63 Tells Investors

On April 14, 2026, QuidelOrtho Corp (QDEL) shares rose 7.7% to a current price of $17.32. Despite today's positive movement, QDEL's stock has experienced signif

Apr 14, 2026 03:20 PM • gurufocus.com

QuidelOrtho Corporation $QDEL Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase and Co. lessened its holdings in QuidelOrtho Corporation (NASDAQ: QDEL) by 85.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,501 shares of the company's stock after selling 746,313 shares during the period. JPMorgan Chase

Apr 04, 2026 12:57 AM • defenseworld.net

Head to Head Comparison: QuidelOrtho (NASDAQ:QDEL) vs. Quipt Home Medical (NASDAQ:QIPT)

Quipt Home Medical (NASDAQ: QIPT - Get Free Report) and QuidelOrtho (NASDAQ: QDEL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Analyst Ratings This is a breakdown of

Mar 31, 2026 09:10 PM • defenseworld.net

QuidelOrtho (NASDAQ:QDEL) Reaches New 52-Week Low – What’s Next?

QuidelOrtho Corporation (NASDAQ: QDEL - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday. The company traded as low as $14.75 and last traded at $15.0080, with a volume of 257918 shares. The stock had previously closed at $15.60. Analysts Set New Price Targets Several brokerages have commented on QDEL.

Mar 28, 2026 10:39 PM • defenseworld.net

Price Targets

RBC Capital Initiates Coverage On QuidelOrtho with Outperform Rating, Announces Price Target of $125

$125.00 (was $92.19)

RBC Capital

Dec 06, 2022 11:43 PM • Benzinga

UBS Upgrades Quidel Corp. (QDEL) to Neutral

$86.00 (was $76.38)

Elizabeth Garcia · UBS

Oct 14, 2022 04:11 AM • StreetInsider